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Cardiopulmonary bypass (CPB) surgery with extracorporeal circulation produce
changes in the immune system and plasma levels of  inflammatory  cytokines. we
hypothesize that Dexmedetomidine as an adjuvant , modulates the inflammatory response
after CABG. In a prospective, randomized, blind study, 31 patients were assigned to
Dexmedetomidine (Dex) group and compared with control group of 30 patients. Dex was
administered at a loading dose of 0.5 µg/kg for 10 min , followed by a continuous infusion
of 0.5 µg/kg per hour until the completion of CABG with CPB .  The endpoints used to
assess inflammatory responses to mini – CPB were plasma tumor necrosis factor (TNF) –
á , interleukin (IL – 6 ) and interleukin ( IL – 10) levels. The inflammatory markers (IL –
6 , IL – 10 , TNF – á ) were determined after Dex administration , before CPB and 24 hours
after admission to ICU. Biochemical factors including glucose , creatinine , lactate , BUN,
AST , ALT , LDH were determined before CPB, immediately after entering the ICU , 24 hr
, 48 hr and 72 hr post admission to ICU. Hemodynamic variables were also determined.
Dex group was associated with a significant reduction in urea and creatinine. There were
no significant differences in glucose, lactate, liver enzymes, LDH , IL – 6, IL – 10 and
hemodynamic variables.  In contrast, the surgery – induced increase in TNF – á levels in
the Dex group was significantly higher compared with the control group.
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Dexmedetomidine (Dex) is a highly
selective á2-adrenergic receptor agonist, that is
used wildly as a sedative and analgesic agent in
the ICU or as an anesthetic adjuvant1. Dex
preserves hemodynamic stability during
cardiopulmonary bypass (CPB) surgery2. In
addition, Dex attenuates the stress responses
caused by intubation and surgery3,4. Due to its
sympatholytic property Dex can decrease the
myocardial oxygen consumption and heart rate
(HR). Major Surgeries produce many complex
changes as well as metabolic, endocrine, and
immune complications called “stress response,”
leading to a prolonged hospitalization. Due to this
systemic response, many postoperative
complications such as respiratory and coagulation
disorders, wound infection, myocardial and
neurologic dysfunction, changes in liver and kidney
function with an increased mortality may occur5 – 7.
Complex interrelated pathways including
generation or activation of cytokines, complement,
neutrophils,   mast cells, thrombin and other
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involved inflammatory mediators, produce
inflammatory responses in CABG patients. Complex
pathophysiological changes in SIRS can be
compared to inflammatory responses at CPB and
remain unclear8.
Several interconnected mechanisms may
have a role in the pathological alterations
associated with CPB, such as blood contact with
non- physiologic surfaces, body temperature
fluctuations, anesthesia, surgical trauma, increased
transmission of bacterial endotoxins across
intestinal membrane and IR (ischemia/reperfusion)
– induced injury9. It leads to a systemic
immunologic response with the release of
arachidonic acid metabolites, endothelins, pro
inflammatory cytokines, platelet-activating factors,
leukocyte and endothelial adhesion molecules into
circulation, causing over production of reactive
oxygen species10,11. Consequently, it is valuable to
investigate the possible benefits of privileged
anesthetic agents with anti-inflammatory capability.
Anesthetic drugs can modulate stress responses
and reduce CABG – induced morbidity and
mortality. Dexmedetomidine, is a potential agent
that little researches has been conducted to clarify
its advantages12. Dexmedetomidine exert  sedative
and anxiolytic properties without respiratory
depression. It has analgesic effect known as “
opioid – sparing “ effect, and is able to  reduce
sympathetic discharge of central nervous system
in a dose-dependent manner. There is certain
evidences that Dexmedetomidine can protect
sensitive organs, like heart, kidney and brain
against IR injury13. However, little knowledge is
available about the exact molecular and cellular
mechanism(s) playing role in dexmedetomidine
protective effects. In this paper, systemic anti –
inflammatory properties and possible
cardioprotective effects of Dexmedetomidine in
CABG, will be discussed.
MATERIALS AND METHODS
61 patients undergoing on – pump CABG,
were scheduled to take part in the study. Patients
who had been divided randomly into two groups
of Dex and control, treated by Dexmedetomidine
(Hospira, Inc, Lake Forest, Il 60045 USA) and
normal saline, respectively. Patients who had
systemic inflammatory diseases, previous heart
surgery, deep hypothermia,  myocardial infarction
within a month before surgery, unstable angina
and severely left ventricular dysfunction (ejection
fraction < 40%) were excluded from study. The
study was confirmed by the Ethics Committee of
the pharmacy school, Islamic Azad University.
Informed consent forms was obtained from all of
the patients before involving in the study. The
patients’ systolic and diastolic blood pressure,
heart rate (HR) and central venous pressure (CVP)
values, were continuously measured and recorded.
The blood pressure, CVP and HR were recorded at
the following times: baseline (before administration
of Dexmedetomidine or normal saline) (T1), after
separation from pump (T2), after entering the ICU
(T3), 6 h after entering the ICU (T4), 12h after
entering the ICU (T5) , 24h after entering the ICU
(T6), 36h after entering the ICU (T7), 48h after
entering the ICU (T8). In the operation room, a
pulse oximetery and ECG leads were continuously
monitored. To measure systemic arterial blood
pressure, A 20 G radial artery catheter was inserted.
A double cavity central venous catheter was placed
into the right internal jugular vein before induction
of anaesthesia. Anesthesia was induced with 10 –
15 µg/kg fentanyl and 0.1 mg/kg midazolam. A bolus
dose of 0.1 mg/kg pavulon was given at 45 min
intervals to facilitate endotracheal intubation.
Anesthesia was maintained by 5 µg/kg/hr fentanyl
and 1 µg/kg/min midazolam after tracheal
intubation. The hypotension, was corrected by
Phenylephrine infusion, when MAP or systolic
pressure decreased below 40 and 80 mmHg,
respectively. Dex was infused at a loading dose of
0.5 µg/kg for 10 min, then Dex infusion was
maintained at a rate of of 0.5 µg/kg/hr until the
completion of the surgery.
Patients were administered Dex pump
infusion at a loading dose of 0.5 µg/kg for 10 min,
followed by a continuous pump infusion of 0.5 µg/
kg/hr until the completion of the surgery. At the
same time, the control group, recieved same
infusion of normal saline. Surgery was started
through a median sternotomy in all of the patients.
The left internal mammary artery (with pedicle) and
the greater saphenous vein were harvested. CPB
was conducted  using a roller pump and membrane
oxygenator. All patients received 10 ml/kg of Ringer
solution before surgery. Deep hypothermia was
induced and the body temperature was maintained
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at 30 – 32 °C. Pharmacological support was given
in accordance with the patients’ hemodynamic
necessities. The surgeons at the operating room
and the nurses at ICU department were blind to
treated regimens.
Central venous blood samples were taken
at times mentioned before. For detection of plasma
levels of inflammatory markers, Blood samples were
centrifuged at 3000 rpm for 10 min, then plasma
were isolated and kept at nitrogen tank, there the
samples were stored at a temperature of 196 °C
below zero until termination of study. The levels of
TNF- alpha, IL-6 and IL-10 were measured by
chemical analysis (commercial kits: Bio Orbit, UK)
by enzyme-linked immunosorbent assay (ELISA).
All assays were performed on the basis of the
manufacturers’ instructions.  In order to measure
other factors, blood samples were directly
transferred to laboratory and were analyzed by
(Auto Analyser Hitachi 917 and 912 RA 1000). Cross
– clamping time, CPB duration and the number of
grafted vessels were also recorded.
Statistical analysis
Statistical analyses were implemented
using stata version 13.0 software program.
Individual data points were considered to be
irrelevent if >2 SD from the mean. Data is s as mean
± SD. Difference in groups were considered
significant if P <0.05. Data was analysed using
Reapeted Measured ANOVA and T test. Statistical
significance in differences between the groups was
presumed when P <0.05.
RESULT
To study the effects of Dexmedetomidine
on the surgical stress responses, first we ignore
any confounding data including age, sex, weights
and comorbidities. However in addiction and
diabetes there were significant differences between
two groups . Patients undergoing CABG with CPB
were randomly allocated into two groups, receiving
either Dex (n=31) or normal saline (n=30). The
obtained information about demographic
Characteristics of patients, showed no significant
differences between two groups (Table 1).
The duration of cross-clamping and CPB,
grafted vessel numbers, inotropic support and
need for blood transfusion showed no significant
variation between two groups (Table 2).
After separation from pump (T2) and
entering the ICU (T3) Dex received patients had
lower SBP (102.03 ± 17.7 at T2 and 104.4 ± 24.2 at
T3 respectively), compared to control group (114.06
± 16.4 at T2 and 118 ± 17.3 at T3) (Table 3).  In
addition, Dex group patients also had a lower DBP
at T3 when compared control group (59 ± 10.3   at
T3 in Dex group and 66.6 ± 13.7 in control group)
(Table 3).
Blood samples were collected from all
patients in both groups and BUN and Creatinine
levels were determined. patients at the two treated
groups had an overall increase in plasma BUN level
after entering the ICU (P<0.01) (Figure 2A).
However, in comparion with control group, Dex
group patients clearly showed decrease in BUN at
72 hr after entering the ICU (P< 0.01). Creatinine
levels at 24 hr after entering the ICU showed
significant
decrease between two groups and it was
lower in Dex treated patients (p<0.05) , the
differences at Creatinine level between two groups
went to be nearly significant (Figure 2B).
Meanwhile, patients in both group showed no
differences at other biochemical endpoints
including AST, ALT, LDH and lactate. (Figure 2C
and Figure 3).
Plasma IL-6 (Figure 1B) levels increased
after CPB compared with baseline. but this increase
was clearly higher in the control group compared
with the Dex group. Plasma TNF-á levels (Figure
1A) were increased after surgery compared with
baseline. However, the increase in TNF-a levels
was significantly higher in the Dex group compared
the control group (p<0.05) . Plasma IL-10 levels
(Figure1C) were sharply increased in both groups
during CABG surgery and decreased after CPB.
Dexmedetomidine did not modify the rate
of decrease in IL-10 levels, the peak level in Dex
group was slightly higher than control group, but
no differences were existed between the two
groups.
DISCUSSION
The main purpose of the present study is
to evaluate the stress response in patients under
CABG with Extracorporeal circulation. The use of
specific anesthetic as anti- inflammatory agents,
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Table 1.  Characteristics of Patients
parameters Dex  group control group P value
(n = 31) (n = 30)
Age (years) 58.4 (10.1) 61.2 (11.7) 0.33
Weight (kg) 72.8 (21.3) 72.6 (15.6) 0.97
BMI  (kg m-2) 1.84 (0.28) 1.81 (0.24) 0.66
LV ejection fraction (%) 43 (9.45) 44.83 (12.41) 0.51
Comorbidities
HLP , n(%) 7 (22.58) 7 (23.33) 0.994
HTN , n(%) 15 (48.39) 19 (65.52) 0.181
Addiction, n(%) 15 (48.39) 7 (23.33) 0.042
Liver diseases, n(%) 0 0 -
Kidney diseases, n(%) 2 (6.45) 1 (3.33) 0.573
Diabetes, n(%) 8 (25.8) 17 (56.67) 0.014
Data are shown as incidence (%) or mean ± (SD). BMI, body mass index; EF,
ejection fraction, HTN, hypertension , HLP, hyperlipidemia
Table 2. Comparison of Surgical Parameters
parameters Dex group Control group P value
Cross-clamping time (min) 46.22 (19.9) 45.03 (22.6) 0.53
Duration of CPB (min) 86.9 (29.1) 88.8 (42.8) 0.89
Number of grafted vessels 3.53 (0.83) 3.53 (0.73) 0.99
Need for Inotropic support , n (%)
Milrinone 0 1(3.33) 0.305
EPI 6(19.35) 8(27.59) 0.451
NEPI 1(3.23) 0 0.329
Blood transfusion
PLT (unit) 0.45(0.88) 0.63(1.03) 0.48
FFP (unit) 0.45(0.99) 0.63(1.21) 0.51
PC (milliliter) 104.8(168) 133.3(204) 0.6
Values are provided as incidence (%) or mean ± (SD).   EPI: epinephrine, NEPI:
norepinephrine, PLT: platelet, FFP: fresh frozen plasma, PC: packed cell
Table 3. Hemodynamic Variables
Data are presented as the mean ± (SD). # P<0.05 as compared to the control group; MAP, mean blood pressure; HR,
heart rate, CVP, central venous pressure.
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Fig. 1. Concentrations of pro inflammatory cytokines
(TNF – á panel A , IL- 6 panel B) and anti inflammatory
cytokine (IL – 10 panel C) at baseline , after completion
of CPB, 24 hr after entering the ICU. Data are represented
as mean (SD). #P < 0.05 vs control
could attenuate these surgical inflammatory
responses and helps to reduce complications at
postoperative recovery period. Activation of the
central á2-adrenergic receptors, leads to reduction
in hemodynamic variables, such as blood pressure
and HR, and consequently modulate the surgical
stress responses. Our study indicates some of the
clinical significance of Dex administration12.
In this study, reduction in hemodynamic
values including the HR, blood pressure and CVP
was observed at Dex group patients, although it
was not significant. Inhibition of central
sympathetic discharge, attenuation of the
peripheral sympathetic tone and stimulation of
vagus nerve, results in a reduction of HR and MAP,
leading to decline in cardiac muscle oxygen
demand and heart afterload, providing heart
protection, particularly in patients suffering from
coronary artery stenosis14. Laryngoscopy and
endotracheal intubation stimulate remarkable
neuro- endocrine responses that increase the risk
of perioperative myocardial ischemia and
infarction. The perioperative administration of
dexmedetomidine may attenuate stress responses
and helps to preserve endocardial perfusion4.
Dexmedetomidine as sympatholytic anesthetic
adjuvant, stables hemodynamic fluctuations
during surgery and recovery period, modifies stress
induced sympatho-adrenal reactions to intubation,
therefore reveals better outcome15.
In this study glucose and lactate values
showed no significant differences between two
groups of patients. There is no obvious information
about Dex inhibitory effects on cortisol synthesis
in humans at short – term studies16 – 18.
In fact, Bekker et al19 assumed  that
intraoperative DEX infusion adjust the severe post
- operative increase in plasma cortisol levels by
reducing stress responses and improvement of
quality of recovery  in patients undergoing major
spinal surgery. However, we did not measure
cortisol levels between the two groups of patients.
Venn et al18 conducted a research to
evaluate the endocrinal, cardiovascular and anti –
inflammatory effects of Dex in cardiac surgery
patients needing ICU sedation.
They concluded that supra therapeutic
concentrations  of dexmedetomidine can inhibit
cortisol synthesis and decrease surgical stress
responses. Mukhtar et al20 understood that
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Fig. 2. Biomarkers of , kidney and myocardial injuries at various time points in patients undergoing CPB. Data are
represented as mean (SD).  #P < 0.05  vs control
dexmedetomidine alleviate hyperglycemic
reactions to surgery significantly compared to
control  group, indicating sympathoadrenal
response suppression.
Tissue ischemia – reperfusion (IR) during
CPB,  activates innate immune system and cytokine
cascade, leads to inflammatory response. This
response is the primary cause of IR  injury, and
could be more harmful than the original surgical
incisions21, 22. Dexmedetomidine may present its
Anti – inflammatory effects through provoking
vagus nerve and stimulation of cholinergic anti –
inflammatory pathways23.
Many reports have been published about
á2 – adrenergic receptor agonists effects on
cytokine and TNF – á production24, 25.
Taniguchi and colleagues26 proved that
Dex prevent cytokines to response against
endotoxemia. One of the possible anti –
inflammatory mechanisims of Dexmedetomidine is
to modulate cytokine production by macrophages
and monocytes. Hofer et al, found that Dex infusion
in Sepsis, can diminish cytokine production27. They
found that preoperative Dex or clonidine
administration in  sepsis – induced rat models,
reduces proinflammatory cytokines such as IL – 1,
IL-6 and TNF – á and finally improves survival
rate. Therefore, they recommended that Dex
administration before surgery, would be a good
option in seriously – ill patients undergoing
CABG28.
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Fig. 3. Bio markers of liver and myocard muscle  injuries.
Data are represented as mean (SD). #P< 0.05 vs control.
Some of these findings are in accordance
with our results but interestingly in our study ,
TNF values in Dex group patients are significantly
higher than control group , This result is in contrast
to previous studies and we do not have a clear
reason to justify it. It is suggested that more
detailed studies be conducted in order to decode
the subject in this regard.
In current study we assess BUN and
Creatinine levels as indicators of renal function .
As yet, no definite strategy for preventing AKI
after cardiac surgery exists. Various factors
including ischemia-reperfusion injury, renal
hypoperfusion, systemic inflammation, and
embolic events, especially in association with
cardiopulmonary bypass (CPB), have been
thought to be responsible for the development of
AKI after cardiac surgery29-31. Hemodynamic
stability, sympathetic activity and renal function
have a close relation. Surgical stress-induced
sympathetic stimulation increases catecholamine
release, resulting in hemodynamic instability
vasoconstriction of  renal arteries, which is noxious
to renal function30. Consequently, Dex
sympatholytic action through á-2 adreno-receptors
activation, is helpful hemodynamic stability and
renal IR injury reduction32 – 34.
Activation of á-2 adrenoreceptors located
on renal vasculature and tubules, prevents renin
secretion, increases glomerular filtration and salt
and water excretion35.
Post – CABG Renal dysfunction increases
serum creatinine, leads to increased mortality and
morbidity, prolonged hospitalization, and more
medical costs36. Dex mechanism of action on renal
function are complex. Alpha- 2 agonists show a
diuretic effect with increased salt and water
excretion37. Several animal studies, demonstrated
possible beneficial effects of Dexmedetomidine on
renal function.
First, dexmedetomidine stimulate
presynaptic á2 receptors, therefore inhibits the
release of sympathetic neurotransmitters
(epinephrine and norepinephrine) into synaptic
space (38,39). Attenuation of sympathicoadrenal
hyperactivity and hemodynamic variations, results
in better preservation of renal function. Second,
Dexmedetomidine activates endothelial a2
adrenoreceptor, which are exist widely in renal
peritubular vesseles and tubules and produces
nitric oxide-induced vaso relaxation40.
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CONCLUSION
In this study, we demonstrated that DEX
could attenuate the increase in IL-6, BUN, serum
creatinine levels and stables hemodynamic
variables. According to this findings Dex has good
effect on kidney function at patients under CABG
surgery with mini-CPB. Despite of our expectations
TNF-á values were significantly higher in Dex
group.  One of our limitations in this study was the
small number of enrolled patients.  So, large-scale
clinical trials are required to further investigate anti-
inflammatory effects of Dex  during major surgeries.
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